ovarian cancer

2 curated biomarkers

← Back to browse

FDA-approved treatments

BRCA1
- Lynparza (olaparib) [fda]
- Talzenna (talazoparib) [fda]
BRCA2
- Lynparza (olaparib) [fda]
- Talzenna (talazoparib) [fda]

Prevalence

BRCA1
Pathogenic germline BRCA1 variants are found in approximately 5% of unselected breast cancers and up to 15% of ovarian cancers.[fda]
BRCA2
Pathogenic germline BRCA2 variants are found in approximately 5% of unselected breast cancers and are also associated with elevated risk of ovarian, pancreatic, and prostate cancer.[fda]

Tests / detection method

BRCA1
germline genetic testing, somatic NGS
BRCA2
germline genetic testing, somatic NGS

Therapeutic pipeline

BRCA1
- Next-generation PARP1-selective inhibitors [fda]
BRCA2
- Next-generation PARP1-selective inhibitors [fda]

PubMed Central · Sep 2, 2026
Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer.
- BRCA1 (biomarker)
Read at PubMed Central
PubMed Central · Sep 2, 2026
VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer.
Read at PubMed Central
PubMed Central · Sep 2, 2026
Non-parametric differential methylation analysis characterizes histotype-specific promoter regions in epithelial ovarian cancer.
Read at PubMed Central
PubMed Central · Sep 1, 2026
The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial.
- BRCA1 (biomarker)
- BRCA2 (biomarker)
Read at PubMed Central
PubMed Central · Sep 1, 2026
HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications.
Read at PubMed Central
PubMed Central · Sep 1, 2026
PiggyBac-Engineered Membrane-Bound IL7 TILs Combined with Anti-PD-1 Antibody Demonstrates Efficacy in Recurrent Ovarian Cancer: A First-in-Human Phase I Trial.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Spatial Integration of Protein and Chromosomal States Reveals Early Copy-Number Changes and Genotype-Associated Immune Neighborhoods in Serous Ovarian Cancer Evolution.
Read at PubMed Central
PubMed Central · Sep 1, 2026
A Multistate Survival Model to Identify Risk Factors for Lethal Ovarian Cancer.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Small Extracellular Vesicle and Total Lipid Profiles Provide a Diagnostic Advantage Over CA-125 Across Ovarian Cancer Subtypes.
Read at PubMed Central
PubMed Central · Sep 1, 2026
A Novel BRCA1 Pathogenic Variant in Tunisian Patient With High Grade Ovarian Cancer: Favorable Therapeutic Response to Olaparib.
- BRCA1 (biomarker)
Read at PubMed Central
PubMed Central · Sep 1, 2026
Altered ANG/TIE gene expression in advanced ovarian cancer is not accompanied by disproportionate body water accumulation relative to perioperative fluid balance.
Read at PubMed Central
PubMed Central · Aug 28, 2026
[Expression of Concern] Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells.
Read at PubMed Central
PubMed Central · Aug 26, 2026
Ascites reprograms innate lymphoid immune cells in ovarian cancer by promoting ILC2 enrichment and dysfunctional NK-cell states.
Read at PubMed Central
PubMed Central · Aug 24, 2026
PCNA-RECQL5-RPRD1B recruit repair components to stressed replication forks to promote survival of BRCA1-deficient cancer cells.
- BRCA1 (biomarker)
Read at PubMed Central
PubMed Central · Aug 24, 2026
A simulation-based comparison of Boruta, LASSO, and Elastic Net for variable selection in logistic regression, with an ovarian cancer miRNA application.
Read at PubMed Central
PubMed Central · Aug 20, 2026
The evaluation of biological effects of artesunate on ovarian cancer using three-dimensional cell culture methods.
Read at PubMed Central
PubMed Central · Aug 20, 2026
The PVR-TIGIT/CD96/CD226 axis: a novel immune checkpoint target in ovarian cancer.
Read at PubMed Central
PubMed Central · Aug 18, 2026
Total moderate-to-vigorous physical activity across the adult life course and the risk of invasive ovarian cancer.
Read at PubMed Central
PubMed Central · Aug 17, 2026
Decision coaching for healthy women with BRCA1/2 pathogenic variants and open family planning: Impact on decisional conflict and decision status: Subgroup analyses from a randomized controlled trial.
- BRCA1 (biomarker)
Read at PubMed Central
PubMed Central · Aug 13, 2026
Ovarian Cancer Stem Cells: Mechanisms of Progression and Therapeutic Strategies.
Read at PubMed Central

ovarian cancer

FDA-approved treatments

Prevalence

Tests / detection method

Therapeutic pipeline

Recent news for ovarian cancer

Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer.

VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer.

Non-parametric differential methylation analysis characterizes histotype-specific promoter regions in epithelial ovarian cancer.

The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial.

HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications.

PiggyBac-Engineered Membrane-Bound IL7 TILs Combined with Anti-PD-1 Antibody Demonstrates Efficacy in Recurrent Ovarian Cancer: A First-in-Human Phase I Trial.

Spatial Integration of Protein and Chromosomal States Reveals Early Copy-Number Changes and Genotype-Associated Immune Neighborhoods in Serous Ovarian Cancer Evolution.

A Multistate Survival Model to Identify Risk Factors for Lethal Ovarian Cancer.

Small Extracellular Vesicle and Total Lipid Profiles Provide a Diagnostic Advantage Over CA-125 Across Ovarian Cancer Subtypes.

A Novel BRCA1 Pathogenic Variant in Tunisian Patient With High Grade Ovarian Cancer: Favorable Therapeutic Response to Olaparib.

Altered ANG/TIE gene expression in advanced ovarian cancer is not accompanied by disproportionate body water accumulation relative to perioperative fluid balance.

[Expression of Concern] Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells.

Ascites reprograms innate lymphoid immune cells in ovarian cancer by promoting ILC2 enrichment and dysfunctional NK-cell states.

PCNA-RECQL5-RPRD1B recruit repair components to stressed replication forks to promote survival of BRCA1-deficient cancer cells.

A simulation-based comparison of Boruta, LASSO, and Elastic Net for variable selection in logistic regression, with an ovarian cancer miRNA application.

The evaluation of biological effects of artesunate on ovarian cancer using three-dimensional cell culture methods.

The PVR-TIGIT/CD96/CD226 axis: a novel immune checkpoint target in ovarian cancer.

Total moderate-to-vigorous physical activity across the adult life course and the risk of invasive ovarian cancer.

Decision coaching for healthy women with BRCA1/2 pathogenic variants and open family planning: Impact on decisional conflict and decision status: Subgroup analyses from a randomized controlled trial.

Ovarian Cancer Stem Cells: Mechanisms of Progression and Therapeutic Strategies.